<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554082</url>
  </required_header>
  <id_info>
    <org_study_id>0304707</org_study_id>
    <secondary_id>00018699</secondary_id>
    <secondary_id>00012098</secondary_id>
    <nct_id>NCT04554082</nct_id>
  </id_info>
  <brief_title>Evaluation of Micronutrients in Obese Patients</brief_title>
  <official_title>Impact of Zinc to Copper Ratio and Lipocalin 2 in Obese Patients Undergoing Sleeve Gastrectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study primarily was to investigate the value of zinc to copper ratio as&#xD;
      possible biomarker of trace elements imbalance in morbidly obese subjects undergoing LSG.&#xD;
&#xD;
      Secondly to correlate zinc to copper ratio with lipocalin 2 (Lcn2) with respect to&#xD;
      Anthropometric measurements and other metabolic biomarkers.&#xD;
&#xD;
      Prospective study will be carried out on 120 morbidly obese adult subjects with a body mass&#xD;
      index (BMI) score above 40 along with presence of obesity-related comorbidity. Investigations&#xD;
      will be measured preoperative and 9 months postoperative after performing Laparoscopic sleeve&#xD;
      gastrectomy; for Body mass index (BMI) and waist circumference. As well as for complete blood&#xD;
      count and biochemical biomarkers as fasting blood glucose, lipid profile, serum iron and&#xD;
      ferritin. Serum Ceruloplasmin, Zn and Cu levels, followed by calculation of zinc to copper&#xD;
      ratio. CRP, serum insulin, serum leptin and lipocalin-2 (Lcn2) will be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONSORT 2010 Flow Diagram&#xD;
&#xD;
      Materials and methods:&#xD;
&#xD;
      Recruitment Morbidly obese subjects attending clinic at Surgery department for laparoscopic&#xD;
      sleeve gastrectomy Alexandria University Hospitals.&#xD;
&#xD;
      Pre-assignment Details adult morbidly obese subjects were included age above 20 years, BMI&#xD;
      above 40 Suffering from comorbidities as hypertension, DM, dyslipidemia. Assigned&#xD;
      participants were clinically evaluated for comorbidities as hypertension, DM, dyslipidemia.&#xD;
&#xD;
      As well as signs of nutritional deficiency as anemia, brittle nails.&#xD;
&#xD;
      Group Information one group of participants eligible for laparoscopic sleeve gastrectomy were&#xD;
      assigned according to their will to participate in study.&#xD;
&#xD;
      Period of evaluation:&#xD;
&#xD;
      First visit: preoperative for clinical assessment of participants, determine BMI and waist&#xD;
      circumference and withdrawal of serum blood sample Second visit: within one month after&#xD;
      surgery to make sure that no complication occurred after surgery.&#xD;
&#xD;
      Third visit: nine months postoperative for revaluation of participants, determine BMI and&#xD;
      waist circumference, and withdrawal of a serum blood sample&#xD;
&#xD;
      Number of participants at initiating the period of study. They were 120 morbidly obese&#xD;
      subjects. Number of participants at the end of the period of study. They were 107 subjects,&#xD;
      13 obese subject withdraw from study as they didn't come during follow up period after 9&#xD;
      months.&#xD;
&#xD;
      Participants according Sex (69 females, and 38 male), with the mean age of 41.6±8.9 years.&#xD;
      The mean preoperative BMI was 47.43±5.4 kg/m2. Then, they were evaluated 9 months after LSG.&#xD;
&#xD;
      Preoperative and Postoperative Clinical characteristics and metabolic variables in studied&#xD;
      subjects.&#xD;
&#xD;
      Preoperative 9 months postoperative P Body weight (Kg) 129.7 ± 12.1 93.4 ±13.6 0.0013* BMI&#xD;
      (kg/m2) 47.43±5.4 35.7±3.8 0.0052* Waist circumference (cm) 130.00 ± 4.68 91.82 ± 3.73 0.001*&#xD;
      Systolic BP (mmHg) 146.0±17.0 132.0±11.0 0.001* Total cholesterol (mmol/L) 5.85 ± 0.41 4.64 ±&#xD;
      0.31 0.035* Triglycerides (mmol/L) 2.20 ± 0.23 1.92 ± 0.24 0.106 HDL cholesterol (mmol/L)&#xD;
      1.23 ± 0.19 1.39 ± 0.2 0.041* LDL cholesterol (mmol/L) 3.37 ± 0.23 2.97 ± 0.21 0.022* HOMA-IR&#xD;
      2.64 ± 1.3 1.44 ± 0.81 0.013* S. Leptin (ng/ml) 102.87 ± 49.16 33.47 ±12.76 0.0001* CRP&#xD;
      (mg/L) 8.4±5.91 3.2±2.98 0.001* Lipocalin 2 (µg/L) 107.24±36.8 51.6±12.73 0.001* Albumin&#xD;
      (g/dl) 4.05±0.21 3.91±0.29 0.113&#xD;
&#xD;
      *Statistically significant at (p≤0.05).&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      primarily was to investigate the value of zinc to copper ratio as possible biomarker of TE&#xD;
      imbalance in morbidly obese subjects undergoing LSG.&#xD;
&#xD;
      For detection of presence of micronutrient deficiency in morbid obesity in form of zinc to&#xD;
      copper ratio and re-evaluate it after loss of weight&#xD;
&#xD;
      Secondly to correlate it with lipocalin 2 (Lcn2) with respect to Anthropometric measurements&#xD;
      and other metabolic markers prospectively.&#xD;
&#xD;
      As zinc to copper ratio is considered as biomarker of micronutrient status; therefore,&#xD;
      correlate it with other biomarkers of inflammation (lipocalin 2) and other parameters as BMI,&#xD;
      FBG to determine if micronutrient status improve after weight loss or not Time frame: 9&#xD;
      months.&#xD;
&#xD;
      Follow-up and outcome parameters:&#xD;
&#xD;
      All studied subjects will be followed up for early postoperative complications (within the&#xD;
      first month) as Bleeding or Leak. Then they will be reviewed after 9 months postoperatively&#xD;
      for assessment of anthropometric measurements, control of preoperative comorbidities, and&#xD;
      manifestations of TE deficiencies (anemia, hair loss, teeth problems, edema. etc.).&#xD;
&#xD;
      Anthropometric parameters&#xD;
&#xD;
      Body mass index (BMI) and waist circumference will be measured preoperative and 9 months&#xD;
      postoperative.&#xD;
&#xD;
      Biochemical parameters&#xD;
&#xD;
      Fasting blood samples will be collected from participants prior to surgery and nine months&#xD;
      postoperative, after overnight fast and divided into two tubes; EDTA for complete blood&#xD;
      count, the rest into plastic tubes and serum sample.&#xD;
&#xD;
      Serum glucose and Total cholesterol, HDL- cholesterol, LDL- cholesterol, and triglyceride,&#xD;
      total protein and Albumin. Serum iron (Fe), and ferritin.&#xD;
&#xD;
      Serum insulin, Ceruloplasmin, Zn and Cu levels, CRP and lipocalin-2 (Lcn2) .&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      All data will be analyzed with Statistical Package for the Social Sciences version 20&#xD;
      software (SPSS, Inc., Chicago, IL). Results will be displayed as mean ± SD. Paired Student's&#xD;
      t-test used to compare the data pre-operative and nine months postoperative. The chi-squared&#xD;
      test used for category variables. Spearman correlation coefficient used to detect the&#xD;
      correlation between different variables. Statistical correlations calculated by Pearson's&#xD;
      correlation test. P &lt; 0.05 is considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of zinc to copper ratio as biomarker of micro-nutrient deficiency</measure>
    <time_frame>nine months</time_frame>
    <description>detect if there are micronutrient deficiency in morbid obesity in form of zinc to copper ratio and re-evaluate it after loss of weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlate zinc to copper ratio to lipocalin 2 and other metabolic biomarkers</measure>
    <time_frame>nine months</time_frame>
    <description>zinc to copper ratio is considered as biomarker of micronutrient status; therefore, it is correlated it with BMI, other biomarkers of inflammation (lipocalin 2) and other parameters as BMI, FBG to determine if micronutrient status improve after weight loss or not</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">107</enrollment>
  <condition>Nutritional Disorder</condition>
  <arm_group>
    <arm_group_label>Preoperative Clinical characteristics and metabolic biomarkers</arm_group_label>
    <description>BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 months' Postoperative metabolic biomarkers</arm_group_label>
    <description>BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic sleeve gastrectomy</intervention_name>
    <description>bariatric surgery to loss weight</description>
    <arm_group_label>9 months' Postoperative metabolic biomarkers</arm_group_label>
    <arm_group_label>Preoperative Clinical characteristics and metabolic biomarkers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples are stored at -80 for determination of serum copper and zinc and lipocalin 2&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult obese subjects with BMI above 40 both males and females presence of obesity&#xD;
        comorbidities as hypertension, insulin resistance &quot;type 2 DM&quot; eligible for laporoscopic&#xD;
        sleeve gatrectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  micronutrient deficiency in morbid obese subjects Adults.&#xD;
&#xD;
          -  BMI above 40&#xD;
&#xD;
          -  presence of comorbidities as hypertenion, DM, dislipidemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  all causes which might cause micronutrient deficiency as presence of gastroesophageal&#xD;
             reflux&#xD;
&#xD;
          -  all causes which may cause increase obesity &quot;BMI&quot; as hormonal disturbance ;&#xD;
             hypothyroidism or cushing, females receiving contraceptive pills&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hala M Demerdash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University Hospitals</affiliation>
  </overall_official>
  <reference>
    <citation>Yerlikaya FH, Toker A, Arıbaş A. Serum trace elements in obese women with or without diabetes. Indian J Med Res. 2013 Feb;137(2):339-45.</citation>
    <PMID>23563378</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 13, 2020</last_update_submitted>
  <last_update_submitted_qc>September 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>hala mourad demerdash</investigator_full_name>
    <investigator_title>Consultant Clinical Pathology</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>zinc</keyword>
  <keyword>copper</keyword>
  <keyword>lipocalin 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT04554082/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT04554082/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

